Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1821 results
August 2018
-
Teaming up with academia to discover medicines
The Novartis Faculty of Scholars initiative connects academic researchers with deep knowledge and big ideas to scientists in its drug discovery labs.
-
Media ReleaseNovartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
-
Media ReleaseNovartis erhält die Zulassung für seine CAR-T-Zell-Therapie Kymriah® (Tisagenlecleucel) von der Europäischen KommissionDie Zulassung durch die EK basiert auf den ersten globalen CAR-T-Zulassungsstudien, an denen Patienten aus acht europäischen Ländern teilnahmen und die ein dauerhaftes Ansprechen und ein…
-
Media ReleaseNovartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episodeTRANSITION shows that Entresto can be safely initiated shortly after an acute heart failure episode, both in the hospital and in an out-patient setting and in a wide range of stabilized patients[1…
-
Key ReleaseSOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutationSOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on or following treatment with an aromatase…
-
Neuroscientists target Alzheimer’s “silent stage”
Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.
-
Key ReleaseNovartis ernennt Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance OfficerBasel, 14. August 2018 - Novartis hat heute die Ernennung von Dr. Klaus Moosmayer zum Chief Ethics, Risk and Compliance Officer bekanntgegeben. Er wird an Vas Narasimhan, M.D., den CEO von…
-
Key ReleaseNovartis appoints Dr. Klaus Moosmayer as Chief Ethics Risk and Compliance OfficerBasel, August 14, 2018 - Novartis announced today the appointment of Dr Klaus Moosmayer as Chief Ethics, Risk and Compliance Officer. He will report to Vas Narasimhan, M.D., CEO of Novartis and…
-
New drug manufacturing tools change pharma chemistry
The modernization and miniaturization of pharmaceutical production could expand the range of ingredients medicinal chemists use to make new drugs.
-
Embracing big data to understand complex diseases
Researchers discover that networks of proteins circulating in the blood influence the development and progression of chronic diseases.
-
Discovery gives cystic fibrosis researchers new direction
Novartis-Harvard team identifies a new type of cell that is key to the disease.
Pagination
- ‹ Previous page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- …
- 152
- › Next page